Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $20.04 USD
Change Today +0.17 / 0.86%
Volume 219.6K
SGNT On Other Exchanges
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Michael Logerfo

President, Chief Legal Officer and Corporate Secretary,Sagent Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 0 board members in 0 different organizations across 1 different industries.

As of Fiscal Year 2014


Mr. Michael Logerfo has been the President of Sagent Pharmaceuticals, Inc. since April 15, 2015 and has been its Corporate Secretary since September 2010. Mr. Logerfo served as the Chief Legal Officer of Sagent Pharmaceuticals, Inc. since April 2010 and served as its Executive Vice President from March 2012 to April 15, 2015 and Corporate Secretary from September 2010 to April 15, 2015. Mr. Logerfo served as Corporate Vice President of Sagent Pharmaceuticals since ...

Read Full Background

Corporate Headquarters*

1901 North Roselle Road
Schaumburg, Illinois 60195

United States

Phone: 847-908-1600
Fax: 847-908-1601

Board Members Memberships*

There is no Board Members Memberships data available.


Georgetown University
Georgetown University

Other Affiliations*

Annual Compensation*

Total Annual Compensation$328,879

Stock Options*

Restricted Stock Awards$119,992
All Other Compensation$8,824
Exercised Options32,759
Exercised Options Value$630,333
Exercisable Options45,958
Exercisable Options Value$650,575
Unexercisable Options24,354
Unexercisable Options Value$145,361
Total Value of Options$1,426,269
Total Number of Options103,071

Total Compensation*

Total Annual Cash Compensation$535,030
Total Short Term Compensation$328,879
Other Long Term Compensation$128,816
Total Calculated Compensation$779,061
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SGNT:US $20.04 USD +0.17


Friedhelm Blobel Ph.D.Chief Executive Officer, President, Executive Director and Member of Business Development Committee
SciClone Pharmaceuticals, Inc.
Douglas A. Michels Chief Executive Officer, President and Director
OraSure Technologies, Inc.
Yongfeng Zhang Ph.D.Chief Executive Officer, Chief Science Officer and Director
Amphastar Pharmaceuticals, Inc.
Aijaz Tobaccowalla Managing Director, Director, Member of Board Administrative & Share Transfer Committee, Member of Nomination & Remuneration Committee, Member of Corporate Social Responsibility Committee and Member of Audit Committee
Pfizer Limited
Douglas L. Drysdale Chairman, Chief Executive Officer and President
Pernix Therapeutics Holdings, Inc.
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SAGENT PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at